Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital
Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital Proceeds from this fundraising will be used to:... View Article
OSE Immunotherapeutics : exercise of option within global license agreement with Janssen
OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation... View Article
OGD2 Pharma and Green Cross LabCell start collaboration
OGD2 Pharma and Green Cross LabCell start collaboration for developing NKcell therapeutics targeting the O-acetyl-GD2 cancer antigen Nantes France & Seoul... View Article
Affilogic enters into a Research Collaboration and Licensing Agreement with Sanofi on Nanofitin-conjugated biotherapeutics
Affilogic announces the signature of a collaboration and license agreement with Sanofi for the development of Nanofitin®-conjugated biotherapeutics. Nantes –... View Article
Biofortis is pleased to announce its cooperation with Triskelion
Biofortis and Triskelion are pleased to announce the partnership signed between Biofortis, the innovation Center of Mérieux Nutrisciences, and Triskelion,... View Article
Maryvonne Hiance Chairman of France Biotech
Atlanpole Biotherapies is pleased to announce the election of one of its iconic entrepreneur : Maryvonne Hiance, who is... View Article
Research Summer School
The University of Angers is very pleased to announce the Summer Schools Angers 2016. From 27th June to 8th July,... View Article
CESTI IHU: INNOVATION TOWARDS IMMUNE SYSTEM MODULATION
CESTI IHU: towards an innovative therapy aiming at modulating the immune system The research program led by Prof. Karin... View Article
XENOTHERA closes a new capital increase above 2 million euros
XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more... View Article
First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line
First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine... View Article